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BACKGROUND
Cisplatin chemotherapy and surgery are effective treatments for children with standard-
risk hepatoblastoma but may cause considerable and irreversible hearing loss. This trial 
compared cisplatin with cisplatin plus delayed administration of sodium thiosulfate, 
aiming to reduce the incidence and severity of cisplatin-related ototoxic effects without 
jeopardizing overall and event-free survival.
METHODS
We randomly assigned children older than 1 month and younger than 18 years of age 
who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, 
and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a 
dose of 80 mg per square meter of body-surface area, administered over a period of 
6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, admin-
istered intravenously over a 15-minute period, 6 hours after the discontinuation of cis-
platin) for four preoperative and two postoperative courses. The primary end point was 
the absolute hearing threshold, as measured by pure-tone audiometry, at a minimum age 
of 3.5 years. Hearing loss was assessed according to the Brock grade (on a scale from 
0 to 4, with higher grades indicating greater hearing loss). The main secondary end 
points were overall survival and event-free survival at 3 years.
RESULTS
A total of 109 children were randomly assigned to receive cisplatin plus sodium thiosul-
fate (57 children) or cisplatin alone (52) and could be evaluated. Sodium thiosulfate was 
associated with few high-grade toxic effects. The absolute hearing threshold was as-
sessed in 101 children. Hearing loss of grade 1 or higher occurred in 18 of 55 children 
(33%) in the cisplatin–sodium thiosulfate group, as compared with 29 of 46 (63%) in the 
cisplatin-alone group, indicating a 48% lower incidence of hearing loss in the cisplatin–
sodium thiosulfate group (relative risk, 0.52; 95% confidence interval [CI], 0.33 to 0.81; 
P = 0.002). At a median of 52 months of follow-up, the 3-year rates of event-free survival 
were 82% (95% CI, 69 to 90) in the cisplatin–sodium thiosulfate group and 79% (95% 
CI, 65 to 88) in the cisplatin-alone group, and the 3-year rates of overall survival were 
98% (95% CI, 88 to 100) and 92% (95% CI, 81 to 97), respectively.
CONCLUSIONS
The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, 
resulted in a lower incidence of cisplatin-induced hearing loss among children with 
standard-risk hepatoblastoma, without jeopardizing overall or event-free survival. (Fund-
ed by Cancer Research UK and others; SIOPEL 6 ClinicalTrials.gov number, NCT00652132; 
EudraCT number, 2007-002402-21.)
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Hepatoblastoma is a rare primary liver cancer with an age-adjusted inci-dence of 0.13 patients per 100,000 pop-
ulation.1 Hepatoblastoma can be categorized as 
standard-risk or high-risk disease according to the 
serum alpha-fetoprotein level in addition to the 
results of the revised Pretreatment Extent of Dis-
ease (PRETEXT) assessment, which includes meta-
static disease.2-4 The combination of cisplatin 
monotherapy and surgery is the standard of care 
for children with standard-risk disease and re-
sults in good long-term survival.5 However, hear-
ing loss constitutes a serious and permanent 
side effect of cisplatin chemotherapy; even mild 
hearing loss may severely affect learning, devel-
opment, and quality of life in young children.6-8 
Key consonants are heard at high frequencies 
(4 kHz through 8 kHz), and so their loss is de-
bilitating, particularly in young children in whom 
speech has not yet developed (see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org).9 Brock grading is used 
to distinguish among hearing-loss levels defined 
as minimal, mild, moderate, marked, or severe 
(grades 0 to 4, respectively) and has a low false 
positive rate as compared with other ototoxicity 
grading systems.10,11 In previous studies conduct-
ed by the International Liver Tumor Strategy 
Group (SIOPEL), more than 60% of the children 
in whom hearing levels were assessed by pure-
tone audiometry had permanent high-frequency 
hearing loss of Brock grade 1 or higher, affect-
ing the frequencies of 8 kHz and below.12 The 
question was whether the risk of hearing loss 
could be reduced by the introduction of an oto-
protectant.
Nonclinical studies and initial phase 1–2 trials 
indicated that sodium thiosulfate has a potential 
otoprotective effect, with maximum efficacy oc-
curring when sodium thiosulfate is administered 
4 to 8 hours after cisplatin,13-20 and that the 
potential tumor-protective effect could be man-
aged.21,22 Pharmacokinetic data and further analy-
sis showed that 6 hours was a safe timing for 
the delayed administration of sodium thiosul-
fate in order to avoid tumor protection.23,24 Since 
children with standard-risk hepatoblastoma can 
be treated with cisplatin alone, they represent an 
appropriate group in which to explore otoprotec-
tion with the delayed administration of sodium 
thiosulfate. Hence, this randomized, phase 3 trial, 
SIOPEL 6, was designed to investigate the ques-
tion of whether delayed administration of sodium 
thiosulfate would reduce the incidence and se-
verity of hearing loss caused by cisplatin.
Me thods
Patients
We conducted this international, cooperative, pro-
spective, randomized trial over a period of 7 years. 
The trial data were blinded for the audiology 
central reviewer. Children younger than 18 years 
of age who had standard-risk hepatoblastoma 
that had not been treated previously were eligi-
ble. Written approval from local research ethics 
committees was obtained, and written informed 
consent was provided by all the parents or legal 
guardians.
Pretreatment Evaluation of Tumor Extent
The intrahepatic extent of tumor at diagnosis was 
assessed by means of ultrasonography of the 
abdomen as well as by computed tomography 
(CT) or magnetic resonance imaging with the 
use of contrast material. Lung metastases were 
identified on CT of the chest. Tumor extent was 
graded according to the PRETEXT system (on a 
scale of I to IV, with higher scores indicating 
increased extent of the disease in the liver) (see 
the Supplementary Appendix). Children with 
PRETEXT I, II, or III hepatoblastoma and with 
no evidence of extrahepatic disease were eligible.2,5
Trial Design, Data Collection, and Analysis
The main trial was designed in line with previ-
ous SIOPEL trials by the first two authors and 
the last author. Platinum–DNA adduct studies 
were designed and carried out by one of the au-
thors at the Northern Institute for Cancer Re-
search, Newcastle University.
A diagnosis of hepatoblastoma on the basis 
of histologic testing, imaging, and an elevated 
serum alpha-fetoprotein level confirming stan-
dard-risk hepatoblastoma were required before 
randomization to the cisplatin group or the cis-
platin–sodium thiosulfate group. Cisplatin was 
administered at a dose of 80 mg per square 
meter of body-surface area in a continuous intra-
venous 6-hour infusion for four preoperative and 
two postoperative courses at 14-day intervals, 
with or without the administration of sodium 
thiosulfate. Tumor response was assessed after 
two and four courses of therapy. Sodium thio-
A Quick Take 
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sulfate at a dose of 20 g per square meter was 
administered intravenously, over a period of 15 
minutes, 6 hours after the end of the cisplatin 
infusion. This dose was chosen to achieve maxi-
mum peak serum levels and effective otoprotec-
tion on the basis of studies involving children 
with central nervous system tumors.16
Radical surgery was attempted after four 
courses or, if the tumor was considered to be 
unresectable, postponed until the end of treat-
ment. The trial design is shown in Figure S1 in 
the Supplementary Appendix. Detailed guide-
lines regarding the adjustment of the cisplatin 
and sodium thiosulfate doses in children weigh-
ing less than 10 kg and regarding hematologic 
and organ toxic effects were provided in the 
protocol (available at NEJM.org), as were guide-
lines for stopping sodium thiosulfate and intro-
ducing doxorubicin in the case of progressive 
disease. Sodium thiosulfate was supplied free of 
charge by Fennec Pharmaceuticals, which had 
no role in the design of the trial, the collection 
or analysis of the data, or the writing of the 
manuscript.
Data were collected by means of a Web-based 
electronic clinical research form that was de-
signed and monitored by the authors in collabora-
tion with Consorzio Interuniversitario (CINECA) 
under the responsibility of the national principal 
investigators. The authors vouch for the accuracy 
and completeness of the data and analyses and 
affirm that the trial was conducted with adher-
ence to the protocol. The first draft of the manu-
script was written by the first author, and the 
SIOPEL 6 trial committee made the decision to 
submit the manuscript for publication. No com-
mercial support for the trial was obtained, and 
no one who is not an author contributed to the 
manuscript. This academic trial was conducted 
and charity-funded in each country under the re-
sponsibility of the national principal investigator.
Adverse events were documented according to 
the National Cancer Institute Common Termi-
nology Criteria for Adverse Events, version 3.0. 
Serious adverse events were defined in accor-
dance with the harmonized tripartite guidelines 
for Good Clinical Practice.
Assessments
Audiologic assessments by means of pure-tone 
audiometry were performed before and through-
out treatment when possible and were performed 
in all the children who were alive at 3.5 years of 
age or older. Audiograms were uploaded, cen-
trally reviewed by one of the authors, and graded 
on the Brock scale (grades 0 to 4) because the 
trial was developed before the 2010 International 
Society of Pediatric Oncology Boston consensus 
ototoxicity grading scale was designed.25 A Brock 
grade of 0 indicates hearing at less than 40 dB 
at all frequencies and does not necessarily equate 
to completely normal hearing. Grades of 1, 2, 3, 
and 4 indicate hearing levels at 40 dB or higher 
at 8 kHz, 4 kHz, 2 kHz, and 1 kHz and above, 
respectively.10 The grade was determined accord-
ing to the hearing level in the child’s better ear.
The primary end point in this trial was the 
absolute hearing threshold, as measured by pure-
tone audiometry, at a minimum age of 3.5 years. 
Secondary end points were the response to pre-
operative chemotherapy, complete resection, com-
plete remission, event-free survival, overall sur-
vival, toxic effects, long-term renal clearance or 
glomerular filtration rate, and the feasibility of 
central audiologic review.
Renal function was monitored at baseline, 
throughout treatment, and at follow-up by mea-
surement of the glomerular filtration rate. When 
possible, this was done by radioisotope (51Cr-EDTA) 
or iohexol methods26,27 or, alternatively, was esti-
mated from the serum creatinine level. At diag-
nosis, a glomerular filtration rate of less than 
75% of the lower limit of the normal range for 
age (<60 ml per minute per 1.73 m2 in children 
>2 years of age) was an exclusion criterion. The 
serum sodium level and blood pressure were 
monitored before, during, and after the admin-
istration of sodium thiosulfate.
The response criteria for the trial were the 
following: complete response (no evidence of 
disease and a normal serum alpha-fetoprotein 
value for age); partial response (any tumor-volume 
shrinkage and a decreased serum alpha-fetopro-
tein level of >1 log below the original measure-
ment); stable disease (no tumor-volume change 
and a decrease of <1 log in the serum alpha-
fetoprotein level); and progressive disease (un-
equivocal increase in the tumor in ≥1 dimen-
sions or any unequivocal increase in the serum 
alpha-fetoprotein level [three successive determi-
nations at intervals of 1 to 2 weeks], even with-
out clinical [physical or radiologic] evidence of 
tumor regrowth). Complete resection was the 
total macroscopic removal of tumor. Total hepa-
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tectomy followed by liver transplantation was 
considered as complete resection and not treat-
ment failure.28 Tumor removal with microscopic 
residual disease, confirmed on histopathological 
testing but not on imaging, was considered as 
complete resection.29 Disease status was deter-
mined at the end-of-treatment visit after the 
postsurgery chemotherapy and was defined as 
complete remission (no evidence of tumor on 
imaging), partial remission (residual tumor or 
an alpha-fetoprotein level above the age-standard-
ized upper limit of the normal range), progres-
sive disease (as defined above), or death. Relapse 
was defined as recurrent tumor detected on imag-
ing and a serial elevation in the serum alpha-feto-
protein level (≥3 consecutive rising values at a 
minimum of weekly intervals) or as recurrent 
tumor detected on imaging, with a normal se-
rum alpha-fetoprotein level, and histologically 
confirmed on biopsy.
Platinum–DNA adduct levels were measured 
in whole-blood samples (5 to 10 ml) that were 
obtained before cisplatin treatment and 24 hours 
after the start of a 6-hour cisplatin infusion. Ad-
duct levels were assessed by inductively coupled 
plasma mass-spectrometry analysis in peripheral-
blood lymphocytes, as described previously.30,31
Statistical Analysis
The trial was designed to have 80% power to 
detect a difference of 25 percentage points in the 
rate of the primary end point of hearing loss of 
grade 1 or higher (a 60% rate of hearing loss in 
the cisplatin-alone group vs. a 35% rate of hear-
ing loss in the cisplatin–sodium thiosulfate 
group) with the use of a chi-square test at a 
significance level of 5%. We used an early-stop-
ping rule for efficacy with O’Brien–Fleming 
boundaries32 and interim analyses involving 34 
children and 68 children who could be evaluated. 
The test statistic for the final analysis was ad-
justed for interim looks and conducted at an alpha 
level of 0.045, with an estimated sample of 102 
children who could be evaluated. A stratified 
Cochran–Mantel–Haenszel test was also per-
formed with adjustment for the stratification 
factors of age at randomization (≤15 months vs. 
>15 months), tumor extent (PRETEXT score of 
I or II vs. III),4 and country.
Overall survival was calculated from the time 
of randomization to death or last follow-up. 
Event-free survival was calculated from the time 
of randomization until disease progression, dis-
ease relapse, second primary cancer, death, or 
last follow-up, whichever came first. The final 
evaluation was conducted once all surviving 
children had reached the age of 3.5 years.
R esult s
Patients
From 2007 through 2014, a total of 116 children 
were enrolled at 52 centers in 12 countries. A 
total of 113 children underwent randomization; 
4 children were found to be ineligible, so the 
intention-to-treat population included 109 chil-
dren. A total of 101 children could be evaluated 
for the primary end point (Fig. S2 in the Supple-
mentary Appendix). The characteristics of the 
patients were well balanced in the two groups 
(Table 1).
Primary End Point and Secondary End Point 
of Feasibility
Figure 1 shows the centrally reviewed Brock 
grading with pure-tone audiometry that was 
performed in children at a minimum age of 
3.5 years. Final audiometry was performed at a 
Characteristic
Cisplatin 
Alone 
(N = 52)
Cisplatin–Sodium 
Thiosulfate 
(N = 57)
Age — mo
Median 13.4 12.8
Range 3.0–70.2 1.2–98.6
Male sex — no. (%) 29 (56) 30 (53)
Alpha-fetoprotein level — ng/ml
Median 73,760 154,638
Range 187–2,175,690 273–4,536,500
PRETEXT score — no. (%)†
I or II 31 (60) 41 (72)
III 21 (40) 16 (28)
*  Cisplatin was administered at a dose of 80 mg per square meter of body-sur-
face area in a 6-hour intravenous infusion. Sodium thiosulfate was adminis-
tered at a dose of 20 g per square meter in a 15-minute intravenous infusion 
6 hours after cisplatin was stopped. There were no significant differences be-
tween the groups in any of the above characteristics.
†  Tumor extent was assessed with the use of the Pretreatment Extent of 
Disease (PRETEXT) system. Scores range from I to IV, with higher scores indi-
cating increased extent of the disease in the liver. Children with a score of IV 
were not included in this trial.
Table 1. Demographic and Clinical Characteristics of the Children  
at Baseline.*
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median of 3 years (range, 3 months to 6.9 years) 
after randomization. The primary end point of 
any hearing loss (defined as grade 1, 2, 3, or 4) 
could be assessed in 101 children. A total of 
5 children died before the definitive hearing as-
sessment, definitive audiometry was not feasible 
for health reasons in 2 children, and the parents 
of 1 child declined further follow-up.
Hearing loss occurred in 18 of 55 children 
(33%; 95% confidence interval [CI], 21 to 47) 
who could be evaluated in the cisplatin–sodium 
thiosulfate group, as compared with 29 of 46 
(63%; 95% CI, 48 to 77) in the cisplatin-alone 
group (P = 0.002 by the chi-square test). The rela-
tive risk of any hearing loss with cisplatin–sodium 
thiosulfate treatment was 0.52 (95% CI, 0.33 to 
0.81), which translates to a 48% lower risk with 
cisplatin–sodium thiosulfate than with cisplatin 
alone. A stratified Cochran–Mantel–Haenszel 
test that was adjusted for the stratification fac-
tors of age at randomization (≤15 months vs. 
>15 months), tumor extent (PRETEXT score of 
I or II vs. III),4 and country resulted in a P value 
of 0.002 (which was lower than the protocol-
specified significance level of 0.045).
Central review of the results of pure-tone 
audiometry was feasible as long as the high fre-
quencies up to 8 kHz had been measured. In 
several cases, repeat audiograms measuring the 
high-frequency range had to be requested.
Efficacy
Results regarding the centrally reviewed response 
to chemotherapy at two and four cycles, surgeries 
performed, and status at the end-of-treatment 
visit and at last follow-up are presented in Ta-
ble 2. A total of 6 children died: 2 children in the 
cisplatin–sodium thiosulfate group and 4 in the 
cisplatin-alone group (1 child in the cisplatin-
alone group had PRETEXT III disease and the 
other 5 children had PRETEXT I or II disease) 
(see the Supplementary Appendix). During or 
after treatment, 11 of 57 children in the cispla-
tin–sodium thiosulfate group and 10 of 52 in the 
cisplatin-alone group had progressive disease 
(6 and 8 children, respectively), relapse (3 and 0), 
or both (2 and 2).
The median follow-up of the patients was 52 
months. The 3-year data regarding overall sur-
vival and event-free survival were similar to those 
previously reported5 and are shown in Figure 2. 
The 3-year rate of overall survival was 98% (95% 
CI, 88 to 100) among children in the cisplatin–
sodium thiosulfate group and 92% (95% CI, 81 
to 97) among those in the cisplatin-alone group. 
The corresponding 3-year rates of event-free sur-
vival were 82% (95% CI, 69 to 90) and 79% (95% 
CI, 65 to 88).
Treatment-Related Adverse Events
Adverse-event data for all 109 children who 
could be evaluated and the numbers of children 
with adverse events of grade 3 or 4 are presented 
in Table 3. The maximum grade of targeted 
events over all cycles is reported according to 
treatment group.
A total of 68 serious adverse events were re-
ported (including 16 serious adverse reactions). 
One unexpected serious adverse reaction was 
reported in a child in whom metabolic acidosis 
developed during the third infusion of sodium 
thiosulfate. The sodium thiosulfate infusion was 
stopped, the child recovered rapidly with fluid 
Figure 1. Hearing Level among 101 Children Who 
Could Be Evaluated.
A Brock grade of 0 indicates hearing at less than 40 dB 
at all frequencies and does not necessarily equate to 
completely normal hearing. Grades 1, 2, 3, and 4 indi-
cate hearing levels at 40 dB or higher at 8 kHz, 4 kHz, 
2 kHz, and 1 kHz and above, respectively.10 The grade 
was determined according to the hearing level in the 
child’s better ear. The numbers of children with each 
Brock grade are provided in Table S2 in the Supple-
mentary Appendix.
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resuscitation, and no further sodium thiosulfate 
was administered in subsequent cycles. The child 
was alive and free from disease 52 months after 
randomization, but grade 4 hearing loss has 
developed. No reason could be found for the 
sudden deterioration in the child’s general con-
dition, so the event was considered by the inves-
tigators to be related to sodium thiosulfate. Of 
the 16 serious adverse reactions, 8 were coded by 
the investigator as being possibly, probably, or 
definitely related to sodium thiosulfate, includ-
ing grade 3 infections in two children, grade 3 
neutropenia in two children, grade 3 anemia 
leading to transfusion in one child, and tumor 
progression in two children. In one child, grade 2 
nausea and vomiting were reported, and the 
parents declined further sodium thiosulfate after 
cycle 2.
Renal Function
Four children (two in each group) had an end-of-
treatment or follow-up assessment in which the 
glomerular filtration rate was less than 60 ml 
per minute per 1.73 m2. The glomerular filtra-
tion rate decreased similarly from baseline to 
follow-up in the two groups, by a median of 
12 ml per minute per 1.73 m2 in the cisplatin–
sodium thiosulfate group and 6 ml per minute 
per 1.73 m2 in the cisplatin-alone group.
Additional Treatment
A total of 21 children (12 children in the cisplatin–
sodium thiosulfate group and 9 in the cisplatin-
alone group) received additional doxorubicin. 
Doxorubicin was administered in 9 children for 
progressive disease (4 children in the cisplatin–
sodium thiosulfate group and 5 in the cisplatin-
alone group) and in 12 for other reasons, 
mainly at the request of the surgeon. In no pa-
tient did the addition of doxorubicin reduce the 
size of the tumor further.
Platinum–DNA Adducts
Blood samples were obtained from 36 children, 
including 24 children (67%) in the cisplatin–
sodium thiosulfate group and 12 (33%) in the 
cisplatin-alone group. Platinum–DNA adduct 
levels ranged from 4.3 to 166 nmol per gram of 
DNA. No correlations were observed between 
platinum–DNA adduct levels and outcome in 
terms of hearing loss, response, or event-free or 
overall survival. Figure S3 in the Supplementary 
Appendix shows the relationship between plati-
num–DNA adduct level and hearing loss.
Response
Cisplatin 
Alone 
(N = 52)
Cisplatin–Sodium 
Thiosulfate 
(N = 57)
no. of patients (%)
Response after two cycles
Partial response 28 (54) 23 (40)
Stable disease 24 (46) 34 (60)
Response after four cycles
Partial response 39 (75) 38 (67)
Stable disease 5 (10) 11 (19)
Progressive disease 5 (10) 5 (9)
Not evaluated† 3 (6) 3 (5)
Resection after preoperative 
chemotherapy
Partial hepatectomy 48 (92) 53 (93)
Liver transplantation 4 (8) 4 (7)
Status at end of treatment
Complete remission 44 (85) 52 (91)
Partial remission 4 (8) 5 (9)
Progressive disease 2 (4) 0
Died 1 (2) 0
Not evaluated 1 (2) 0
Status at last follow-up
Complete remission 48 (92) 55 (96)
Partial remission 0 0
Recurrent disease 0 0
Died‡ 4 (8) 2 (4)
*  The response criteria are explained in the Methods section. Doxorubicin may 
have been administered in cases of progressive disease (or for other reasons, 
such as a surgeon’s request). A total of 21 children received 1 to 6 courses of 
doxorubicin during initial therapy, including 9 children in the cisplatin-alone 
group (who received a total of 30 courses) and 12 in the cisplatin–sodium 
thiosulfate group (who received a total of 28 courses).
†  In the cisplatin-alone group, response in two children was not evaluated after 
four cycles, and treatment in one child was switched to a dose-dense regi-
men, on the basis of the International Liver Tumor Strategy Group (SIOPEL) 
4 study,33 at the request of the surgeon. In the cisplatin–sodium thiosulfate 
group, two children had a response that had been sufficiently good for them 
to undergo surgery after three cycles, which made them unable to be evaluat-
ed for chemotherapy response after four cycles, and response was not evalu-
ated in one child after four cycles.
‡  The deaths in the cisplatin-alone group were due to surgical complications  
(in one child), due to cardiac arrest after treatment with paclitaxel after pro-
gression (in one), and due to disease (in two). The two deaths in the cisplatin–
sodium thiosulfate group were due to disease.
Table 2. Status after Preoperative Chemotherapy.*
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Discussion
In this trial, the addition of delayed sodium 
thiosulfate to cisplatin led to a 48% lower risk of 
hearing loss. Hearing loss of grade 1 or higher 
occurred in 63% of the children who did not 
receive otoprotection, as compared with 33% of 
those who did. The administration of sodium 
thiosulfate was associated with a trend toward 
reduced ototoxicity in all the Brock grades. Chil-
dren with hearing of grade 0 may not have com-
pletely normal hearing but can manage life with 
little or no additional help. Children with hear-
ing loss of grade 1 or higher typically receive 
further intervention with each increasing grade 
of hearing loss, with children with any grade of 
hearing loss receiving educational support. In the 
United Kingdom, young children with hearing 
loss of grade 1 and all children with hearing loss 
of grade 2 or 3 are offered hearing aids. Chil-
dren with hearing loss of grade 4 are offered 
cochlear implants. Similar reductions in the 
incidence and severity of cisplatin-induced oto-
toxic effects were reported with the delayed 
administration of sodium thiosulfate in the 
ACCL0431 trial.34,35 The effect of high-frequency 
hearing loss and hearing support varies across 
the world, the reasons for which are multifacto-
rial but include the variation in sound frequen-
cies that are used in different languages. The 
analysis of these variables was beyond the scope 
of this trial.
In this trial, progressive tumor developed in 
the same number of children in each group. 
There was no significant difference in the rates 
of event-free survival or overall survival between 
the two groups.
The incidence of acute adverse events was as 
expected,5,36 and an unexpected reaction devel-
oped in one child. Neither hypertension nor a 
high serum sodium level resulted in the discon-
tinuation of sodium thiosulfate treatment in any 
of the children. The otoprotective dose of sodium 
thiosulfate was associated with a high sodium 
load, which is a factor to consider in planning 
treatment. Sodium thiosulfate was emetogenic 
despite the use of prophylactic antiemetic agents, 
with nausea and vomiting being common ad-
verse events. Sodium thiosulfate did not alter the 
use of 24-hour hydration after the administra-
tion of cisplatin. Renal function was acceptable 
in these young children, with four children having 
a glomerular filtration rate of less than 60 ml 
per minute per 1.73 m2 at the end of treatment 
or follow-up.26,37 The initiation of sodium thio-
sulfate after a 6-hour delay from the comple-
tion of cisplatin administration caused no tumor 
protection and did not adversely affect disease 
outcome.
Platinum–DNA adduct formation as measured 
in peripheral-blood lymphocytes showed no cor-
Figure 2. Event-free Survival and Overall Survival.
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relation between adduct levels and outcome in 
terms of hearing loss or clinical response. This 
finding confirms results from previous studies 
suggesting that the quantification of platinum–
DNA adduct levels in peripheral-blood lympho-
cytes does not provide a useful biomarker of 
patients’ response or platinum-induced toxic ef-
fects because of a lack of correlation between 
adduct levels in lymphocytes and those in tumor 
and other host tissues.30,38,39 Recent evidence 
suggests that cisplatin-induced ototoxic effects 
are associated with long-term retention of cis-
platin, specific to the cochlea.40
In conclusion, in this randomized, phase 3 
trial involving children with localized hepato-
blastoma who were undergoing chemotherapy 
with cisplatin alone or cisplatin plus sodium 
thiosulfate, we found that the delayed adminis-
tration of sodium thiosulfate resulted in a signifi-
cantly lower incidence of cisplatin-induced hear-
ing loss, with no evidence of tumor protection.
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Adverse Event and Grade
Cisplatin 
Alone 
(N = 52)
Cisplatin–Sodium 
Thiosulfate 
(N = 57)
no. of patients (%)
Allergy, grade 3 1 (2) 0
Febrile neutropenia, grade 3 10 (19) 8 (14)
Infection, grade 3 16 (31) 13 (23)
Hypomagnesemia, grade 3 1 (2) 1 (2)
Hypernatremia, grade 3 0 1 (2)
Vomiting, grade 3 2 (4) 4 (7)
Nausea, grade 3 3 (6) 2 (4)
Left ventricular systolic dysfunction,  
grade 3 or 4
0 0
Renal event, grade 3 or 4 0 0
Anemia
Grade 3 8 (15) 10 (18)
Grade 4 0 1 (2)
Leukopenia, grade 3 2 (4) 2 (4)
Neutropenia
Grade 3 3 (6) 7 (12)
Grade 4 3 (6) 3 (5)
Thrombocytopenia
Grade 3 1 (2) 1 (2)
Grade 4 1 (2 1 (2)
Gastrointestinal event 2 (4) 3 (5)
Elevated liver-enzyme level
Grade 3 6 (12) 3 (5)
Grade 4 0 1 (2)
Elevated serum glucose level, grade 3 2 (4) 1 (2)
Hypermagnesemia, grade 3† 2 (4) 5 (9)
Hypophosphatemia, grade 3 0 5 (9)
Hyperkalemia, grade 3 2 (4) 0
Hypokalemia
Grade 3 0 4 (7)
Grade 4 0 1 (2)
Dyspnea, grade 3 1 (2) 0
*  If grade 4 is not shown, there was no grade 4 adverse event. This table includes 
adverse events that were associated with additional treatment (mostly doxoru-
bicin) given to children in each group.
†  The protocol specified the addition of magnesium to the hydration fluid ad-
ministered with cisplatin therapy.
Table 3. Children with Grade 3 or 4 Adverse Events.*
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